Brookes Pharma (Pvt) Limited

INTER OFFICE MEMO

Date To From C. C. Re : : : : : Sunday, February 10, 2013 All Regional Manager Senior Product Manager DM,CSM, Sr. MAM Dostin - Pilot Talk Ref. No.:

All of you are well aware the Brookes were the 1st company who launched Erdosteine, with the international brand name of Dostin in collaboration and under the License of Edmond Pharma Italy. As you know that Dostin is a mucolytic agent of newer generation, therefore, this cannot be treated as yet another Mucolytic like N- Carbocyctine or Ambroxol. The same has to be promoted in the call that Dostin is a different Mucolytic and well documented. Since it is newer generation of mucolytic agent therefore, it has different activities too. Dostin has the following tetradynamic activity, which is not with other available mucolytic. : o Muco-Modulatory o Anti-Oxidant o Bacterial Anti-Adhesion o Bronchial Anti- Inflammatory effects As such being the licensee in Pakistan we have the responsibility to promote the Dostin with its appropriate scientific information we receive. Keeping in view the importance of Dostin we have develop a new 2-page folder for an aggressive promotion. Furthermore, please note that Dostin group sales are not as per the set targets and it seems that it is not promoted properly. Therefore, with the help of this folder as RSM you are advised to keep the same pace of promotion as of Nezocin and other products. To further facilitate all the field force we enclose herewith the Pilot-Talk of Dostin. You are advised to a arrange group session of your respective field force and discuss each line and objectives of Dostin. Let the SPOs understand and memorize each line and each word of pilot talk and literature. Do the practice again and again. We hope that the pilot-talk will provide you ample information for an effective promotion of Dostin to all specialties with the surety in mind that Brookes is the pioneer of Erdosteine in Pakistan market. Therefore, you have to make sure for an effective call for acceleration of RXs so that you must achieve targets of all presentations. For any further quarry or explanation do not hesitate to contact us. Best regards

Syed Saud Aziz